Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-020-0323-4 http://scihub22266oqcxt.onion/10.1038/s41577-020-0323-4 32346094!7187801!32346094     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32346094.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Rev+Immunol 2020 ; 20 (6): 347-348 Nephropedia Template TP {{tp|p=32346094|t=2020. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}{{32346094}} gab.com Text COVID-19 vaccine design: the Janus face of immune enhancement JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32346094 #FOAvip Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy. Twit Text FOAVip COVID-19 vaccine design: the Janus face of immune enhancement ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32346094 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32346094 #FOAvip English Wikipedia <ref>{{Cite pmid|32346094}}</ref> COVID-19 vaccine design: the Janus face of immune enhancement #MMPMID32346094 Hotez PJ; Corry DB; Bottazzi ME Nat Rev Immunol 2020[Jun]; 20 (6): 347-348 PMID32346094show ga Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy. |*Drug Design[MESH] |*Viral Vaccines/immunology[MESH] |Animals[MESH] |Antibodies, Viral/immunology[MESH] |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |COVID-19 Vaccines[MESH] |Clinical Laboratory Techniques[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/diagnosis/*immunology/prevention & control[MESH] |Humans[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*immunology/prevention & control[MESH]COVID-19 vaccine design: the Janus face of immune enhancement (epmc).pdf DeepDyve Pubget Overpricing